DONALD AMMERMAN: Open Payments
NPI 1316032295 · DANBURY, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$411,966 in 505 payments from 7 companies in 2025. Trend: 2023 $251,336 · 2024 $279,657 · 2025 $411,966
Speaker / faculty: $367,823Travel & lodging: $23,449Food & beverage: $10,774Consulting: $9,920
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 150 | $133,065 |
| ABBVIE INC. | 162 | $132,253 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 121 | $112,901 |
| Vanda Pharmaceuticals Inc. | 57 | $33,524 |
| E.R. Squibb & Sons, L.L.C. | 11 | $135 |
| Teva Pharmaceuticals USA, Inc. | 3 | $66 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
Products named: INGREZZA, VRAYLAR, CAPLYTA, FANAPT, COBENFY, UZEDY, AUSTEDO XR, REXULTI.
Industry payments across CT — which companies pay providers there.
